论文部分内容阅读
目的探讨长春瑞滨或紫杉醇联合顺铂治疗晚期乳腺癌的疗效和不良反应。方法 130例患者随机分为两组,分别为长春瑞滨联合顺铂组(NP方案组)和紫杉醇联合顺铂(TP方案组),每组患者65例,NP方案组患者给予长春瑞滨50 mg/d,d1、d8;;顺铂30 mg/m2,d1-d5。TP方案组患者给予紫杉醇110～140 mg/m2,d2;顺铂30 mg/m2,d1-d5。结果 NP方案总有效率为61.4%(40/65),中位生存期为7.5个月;TP方案总有效率55.4%(36/65),中位生存期7.2个月。两组比较差异无统计学意义(P>0.05)。结论 NP方案与TP方案治疗晚期乳腺癌患者疗效相当,都可以作为治疗晚期乳腺癌治疗的临床方案。
Objective To investigate the efficacy and adverse reactions of vinorelbine, paclitaxel and cisplatin in the treatment of advanced breast cancer. Methods 130 patients were randomly divided into two groups: vinorelbine plus cisplatin (NP group) and paclitaxel plus cisplatin (TP group), 65 patients in each group, NP regimen group were given Vinorelbine 50 mg / d, d1, d8 ;; cisplatin 30 mg / m2, d1-d5. Patients in the TP regimen received paclitaxel 110-140 mg / m2, d2; cisplatin 30 mg / m2, d1-d5. Results The total effective rate of NP was 61.4% (40/65) and the median survival was 7.5 months. The total effective rate of TP was 55.4% (36/65) and the median survival was 7.2 months. There was no significant difference between the two groups (P> 0.05). Conclusion NP and TP regimens in the treatment of patients with advanced breast cancer have comparable efficacy and can be used as a clinical regimen for the treatment of advanced breast cancer.